Interleukin-6 stimulates defective angiogenesis

Cancer Research

Volumn 75, Issue 15, 2015, Pages 3098-3107

  Gopinathan, Ganga ^a   Milagre, Carla ^a   Pearce, Oliver M T ^a   Reynolds, Louise E ^a   Hodivala Dilke, Kairbaan ^a   Leinster, David A ^a   Zhong, Haihong ^b   Hollingsworth, Robert E ^b   Thompson, Richard ^a   Whiteford, James R ^a   Balkwill, Frances ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; INTERLEUKIN 6; JAGGED1; MEDI 5117; MESSENGER RNA; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN; C11ORF2 PROTEIN, HUMAN; CALCIUM BINDING PROTEIN; IL6 PROTEIN, HUMAN; MEMBRANE PROTEIN; SERRATE PROTEINS; SIGNAL PEPTIDE; VASCULOTROPIN A; VESICULAR TRANSPORT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER THERAPY; CELL MIGRATION; CELL PROLIFERATION; CELL STIMULATION; CEREBROVASCULAR ACCIDENT; CHRONIC INFLAMMATION; CONTROLLED STUDY; DRUG TARGETING; ENDOTHELIUM CELL; EX VIVO STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OVARY CANCER; PERICYTE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; RAT; THORACIC AORTA; TUMOR BIOPSY; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; VASCULAR RING; ANIMAL; AORTA; BAGG ALBINO MOUSE; C57BL MOUSE; CHEMICALLY INDUCED; DRUG EFFECTS; DRUG SCREENING; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; ORGAN CULTURE TECHNIQUE; OVARY TUMOR; PATHOLOGY; PROCEDURES; TUMOR CELL LINE; WISTAR RAT;

ANIMALS; AORTA; CALCIUM-BINDING PROTEINS; CELL LINE, TUMOR; ENDOTHELIAL CELLS; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-6; MALE; MEMBRANE PROTEINS; MICE, INBRED BALB C; MICE, INBRED C57BL; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; ORGAN CULTURE TECHNIQUES; OVARIAN NEOPLASMS; PERICYTES; RATS, WISTAR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VESICULAR TRANSPORT PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84942871336     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-1227     Document Type: Article

References (40)

1. Taniguchi K, Karin M. IL6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin Immunol 2014; 26: 54-74.
2. Hong DS, Angelo LS, Kurzrock R. Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer 2007; 110: 1911-28.
3. Ancrile B, Lim KH, Counter CM Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev 2007; 21: 1714-9.
4. Grivennikov S, Karin E, Terzic J., Mucida D, Yu GY, Vallabhapurapu S, et al IL6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009; 15: 103-13.
5. Chang Q, Bournazou E, Sansone P., Berishaj M, Gao SP, Daly L, et al The IL6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. Neoplasia 2013; 15: 848-62.
6. Kulbe H, Chakravarty P, Leinster D.A., Charles KA, Kwong J, Thompson RG, et al A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Res 2012; 72: 66-75.
7. Coward J, Kulbe H, Chakravarty P., Leader D, Vassileva V, Leinster D.A., et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res 2011; 17: 6083-96.
8. Stone RL, Nick AM, McNeish I.A., Balkwill F., Han HD, Bottsford-Miller J, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 2012; 366: 610-8.
9. Nilsson MB, Langley RR, Fidler IJ Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res 2005; 65: 10794-800.
10. Xu Q, Briggs J, Park S., Niu G, Kortylewski M, Zhang S., et al. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 2005; 24: 5552-60.
11. Yao JS, Zhai W, Young W.L., Yang GY. Interleukin-6 triggers human cerebral endothelial cells proliferation and migration: the role for KDR and MMP-9. Biochem Biophys Res Commun 2006; 342: 1396-404.
12. Fan Y, Ye J, Shen F., Zhu Y, Yeghiazarians Y, Zhu W., et al. Interleukin-6 stimulates circulating blood-derived endothelial progenitor cell angiogenesis in vitro. J Cereb Blood Flow Metab 2008; 28: 90-8.
13. de Groot J., Liang J, Kong L.Y., Wei J., Piao Y, Fuller G, et al Modulating antiangiogenic resistance by inhibiting the signal transducer and activator of transcription 3 pathway in glioblastoma. Oncotarget 2012; 3: 1036-48.
14. Kwon KA, Kim SH, Oh S.Y., Lee S., Han JY, Kim KH, et al. Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer. BMC Cancer 2010; 10: 203.
15. Nicosia RF. The aortic ring model of angiogenesis: a quarter century of search and discovery. J Cell Mol Med 2009; 13: 4113-36.
16. Reynolds LE, Hodivala-Dilke KM. Primary mouse endothelial cell culture for assays of angiogenesis. Methods Mol Med 2006; 120: 503-9.
17. Cohen T, Nahari D, Cerem L.W., Neufeld G., Levi BZ. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 1996; 271: 736-41.
18. Patel NS, Dobbie MS, Rochester M, Steers G., Poulsom R, Le Monnier K, et al. Up-regulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer. Clin Cancer Res 2006; 12: 4836-44.
19. Scehnet JS, Jiang W, Kumar S.R., Krasnoperov V., Trindade A, Benedito R, et al Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Blood 2007; 109: 4753-60.
20. Schadler KL, Zweidler-McKay PA, Guan H., Kleinerman ES. Delta-like ligand 4 plays a critical role in pericyte/vascular smooth muscle cell formation during vasculogenesis and tumor vessel expansion in Ewing's sarcoma. Clin Cancer Res 2010; 16: 848-56.
21. Benedito R, Roca C, Sörensen I, Adams S., Gossler A, Fruttiger M, et al The notch ligands Dll4 and Jagged1 have opposing effectson angiogenesis. Cell 2009; 137: 1124-35.
22. Kume T. Novel insights into the differential functions of Notch ligands in vascular formation. J Angiogenesis Res 2009; 1: 8.
23. Gerhardt H, Semb H. Pericytes: gatekeepers in tumour cell metastasis? J Mol Med 2008; 86: 135-44.
24. Qin D, Trenkwalder T, Lee S, Chillo O, Deindl E, Kupatt C, et al. Early vessel destabilization mediated by Angiopoietin-2 and subsequent vessel maturation via Angiopoietin-1 induce functional neovasculature after ischemia. PLoS ONE 2013; 8: e61831.
25. Feng Y, vom Hagen F, Pfister F, Djokic S., Hoffmann S, Back W, et al. Impaired pericyte recruitment and abnormal retinal angiogenesis as a result of angiopoietin-2 overexpression. Thromb Haemost 2007; 97: 99-108.
26. Hammes HP, Lin J, Wagner P., Feng Y, Vom Hagen F, Krzizok T, et al Angiopoietin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy. Diabetes 2004; 53: 1104-10.
27. Keskin D, Kim J, Cooke V.G., Wu CC, Sugimoto H, Gu C, et al Targeting vascular pericytes in hypoxic tumors increases lung metastasis via angiopoietin-2. Cell Rep 2015; 10: 1066-81.
28. Ribatti D, Nico B, Crivellato E. The role of pericytes in angiogenesis. Int J Dev Biol 2011; 55: 261-8.
29. Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions. Circ Res 2005; 97: 512-23.
30. Gertz K, Kronenberg G, Kalin R.E., Baldinger T., Werner C, Balkaya M, et al Essential role of interleukin-6 in post-stroke angiogenesis. Brain 2012; 135: 1964-80.
31. Kayakabe K, Kuroiwa T, Sakurai N, Ikeuchi H, Kadiombo AT, Sakairi T, et al. Interleukin-6 promotes destabilized angiogenesis by modulating angiopoietin expression in rheumatoid arthritis. Rheumatology 2012; 51:1571-9.
32. Xian X, Hakansson J, Stahlberg A., Lindblom P, Betsholtz C, Gerhardt H., et al. Pericytes limit tumor cell metastasis. J Clin Invest 2006; 116: 642-51.
33. Cooke VG, LeBleu VS, Keskin D, Khan Z., O'Connell JT, Teng Y, et al Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell 2012; 21: 66-81.
34. Jo MJ, Lee JH, Nam B.H., Kook MC, Ryu KW, Choi IJ, et al Preoperative serum angiopoietin-2 levels correlate with lymph node status in patients with early gastric cancer. Ann Surg Oncol 2009; 16: 2052-7.
35. Sfiligoi C, de Luca A, Cascone I, Sorbello V., Fuso L, Ponzone R, et al. Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival. Int J Cancer 2003; 103: 466-74.
36. Schulz P, Fischer C, Detjen K.M., Rieke S., Hilfenhaus G, von Marschall Z, et al. Angiopoietin-2 drives lymphatic metastasis of pancreatic cancer. FASEB J 2011; 25: 3325-35.
37. Monk BJ, Poveda A, Vergote I., Raspagliesi F, Fujiwara K, Bae D.S., et al. Antiangiopoietin therapy with trebananib for recurrent ovarian cancer (TRI-NOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 2014; 15: 799-808.
38. Jain RK, Duda DG, Willett C.G., Sahani DV, Zhu AX, Loeffler JS, et al Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009; 6: 327-38.
39. Willett CG, Duda DG, diTomaso E, Boucher Y., Ancukiewicz M, Sahani DV, et al Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 2009; 27: 3020-6.
40. Zhu AX, Sahani DV, Duda D.G., di Tomaso E, Ancukiewicz M, Catalano O.A., et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009; 27: 3027-35.